Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naïve to anti-TNF treatment
William J. Sandborn(University of San Diego), Gary Lichtenstein(University of Pennsylvania), Stephen B. Hanauer(Northwestern University), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Ralph Bloomfield(AstraZeneca (United Kingdom)), J F Colombel(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k